Rigel Pharmaceuticals | RIGL - Işletim Giderleri





Işletim Giderleri Değişiklik Tarih
Agenus USD 19.81M 293.94M 2025-12
Amgen USD 5.9B 773M 2025-12
Anika Therapeutics USD 29.97M 116.84M 2025-12
Arrowhead Research USD 223.22M 10.86M 2025-12
AstraZeneca USD 12.53B 4.16B 2025-12
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Celldex Therapeutics USD 87.27M 511.09M 2025-12
Daiichi Sankyo JPY 468.57B 15.34B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Halozyme Therapeutics USD 211.07M 74.73M 2025-12
Heron Therapeutics USD 40.55M 1.46M 2025-12
Intrexon USD 61.56M 26.1M 2024-06
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
Karyopharm Therapeutics USD 61.82M 3.24M 2024-12
Ligand Pharmaceuticals USD 8.29M 32.17M 2025-09
MacroGenics USD 53.32M 13.68M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Veracyte USD 116M 7.24M 2025-12